Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocyte leukemia

Neil Elliot Kay, R. T. Perri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The clonal excess of B cells in B-chronic lymphocytic leukemia (B-CLL) plays an important part in the basic disease process, secondary lymphomas, and autoimmune phenomema. Detailed investigations to characterize the dysfunction of the B-CLL B cell have been limited by misplaced beliefs that the clonal B-CLL B cell is 'well differentiated' and 'inert immunologically'. Many investigations have demonstrated that B-CLL B cells are not inert, but may be induced to further differentiate in the presence of the appropriate immunoregulatory signal(s). Recent studies have identified that normal B-cell function involved a complicated and multiphasic process consisting of an activation process, a proliferative response, and a final differentiation stage. It is not clear how the malignant B-cell dysfunction in B-CLL relates to these defined processes of normal B-cell function. The ability to precisely define the nature of the defects in the clonal B cells of B-CLL might provide a more complete understanding of the relationship of these cells to normal B-cell development and differentiation and, thus, alter our current perspectives on the pathophysiology and therapy of B-CLL.

Original languageEnglish (US)
Pages (from-to)163-177
Number of pages15
JournalClinics in Laboratory Medicine
Volume8
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Lymphocytes
B-Cell Chronic Lymphocytic Leukemia
Leukemia
B-Lymphocytes
B-Cell Leukemia
Cells
Cell Differentiation
Lymphoma
Chemical activation
Defects

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocyte leukemia. / Kay, Neil Elliot; Perri, R. T.

In: Clinics in Laboratory Medicine, Vol. 8, No. 1, 1988, p. 163-177.

Research output: Contribution to journalArticle

@article{4ed2880c45ba4c14961fa6b727b0db9a,
title = "Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocyte leukemia",
abstract = "The clonal excess of B cells in B-chronic lymphocytic leukemia (B-CLL) plays an important part in the basic disease process, secondary lymphomas, and autoimmune phenomema. Detailed investigations to characterize the dysfunction of the B-CLL B cell have been limited by misplaced beliefs that the clonal B-CLL B cell is 'well differentiated' and 'inert immunologically'. Many investigations have demonstrated that B-CLL B cells are not inert, but may be induced to further differentiate in the presence of the appropriate immunoregulatory signal(s). Recent studies have identified that normal B-cell function involved a complicated and multiphasic process consisting of an activation process, a proliferative response, and a final differentiation stage. It is not clear how the malignant B-cell dysfunction in B-CLL relates to these defined processes of normal B-cell function. The ability to precisely define the nature of the defects in the clonal B cells of B-CLL might provide a more complete understanding of the relationship of these cells to normal B-cell development and differentiation and, thus, alter our current perspectives on the pathophysiology and therapy of B-CLL.",
author = "Kay, {Neil Elliot} and Perri, {R. T.}",
year = "1988",
language = "English (US)",
volume = "8",
pages = "163--177",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocyte leukemia

AU - Kay, Neil Elliot

AU - Perri, R. T.

PY - 1988

Y1 - 1988

N2 - The clonal excess of B cells in B-chronic lymphocytic leukemia (B-CLL) plays an important part in the basic disease process, secondary lymphomas, and autoimmune phenomema. Detailed investigations to characterize the dysfunction of the B-CLL B cell have been limited by misplaced beliefs that the clonal B-CLL B cell is 'well differentiated' and 'inert immunologically'. Many investigations have demonstrated that B-CLL B cells are not inert, but may be induced to further differentiate in the presence of the appropriate immunoregulatory signal(s). Recent studies have identified that normal B-cell function involved a complicated and multiphasic process consisting of an activation process, a proliferative response, and a final differentiation stage. It is not clear how the malignant B-cell dysfunction in B-CLL relates to these defined processes of normal B-cell function. The ability to precisely define the nature of the defects in the clonal B cells of B-CLL might provide a more complete understanding of the relationship of these cells to normal B-cell development and differentiation and, thus, alter our current perspectives on the pathophysiology and therapy of B-CLL.

AB - The clonal excess of B cells in B-chronic lymphocytic leukemia (B-CLL) plays an important part in the basic disease process, secondary lymphomas, and autoimmune phenomema. Detailed investigations to characterize the dysfunction of the B-CLL B cell have been limited by misplaced beliefs that the clonal B-CLL B cell is 'well differentiated' and 'inert immunologically'. Many investigations have demonstrated that B-CLL B cells are not inert, but may be induced to further differentiate in the presence of the appropriate immunoregulatory signal(s). Recent studies have identified that normal B-cell function involved a complicated and multiphasic process consisting of an activation process, a proliferative response, and a final differentiation stage. It is not clear how the malignant B-cell dysfunction in B-CLL relates to these defined processes of normal B-cell function. The ability to precisely define the nature of the defects in the clonal B cells of B-CLL might provide a more complete understanding of the relationship of these cells to normal B-cell development and differentiation and, thus, alter our current perspectives on the pathophysiology and therapy of B-CLL.

UR - http://www.scopus.com/inward/record.url?scp=0023907022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023907022&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 163

EP - 177

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 1

ER -